Search Results - Rojkjaer, L

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttal

    Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttal by SALLAH, S., ISAKSEN, M., SEREMETIS, S., PAYNE ROJKJAER, L.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS

    LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS by Kolstad, A., Madsbu, U., Beasley, M., Bayne, M., Illidge, T., O'Rourke, N., Lagerlöf, I., Hájek, R., Jurczak, W., Willenbacher, E., Blakkisrud, J., Muftuler Løndalen, A., Rojkjaer, L., Baylor Curtis, L., Bloma, M., Turner, S., Bolstad, N., Spetalen, S., Erlanson, M., Nygaard, S., Holte, H.

    Published in Hematological oncology
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    54 A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION TRIAL USING THE ONCE-DAILY ORAL CHELATOR DEFERASIROX TO TREAT IRON OVERLOAD IN HFE-RELATED HEREDITARY HEMOCHROMATOSIS

    54 A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION TRIAL USING THE ONCE-DAILY ORAL CHELATOR DEFERASIROX TO TREAT IRON OVERLOAD IN HFE-RELATED HEREDITARY HEMOCHROMATOSIS by Pietrangelo, A, Brissot, P, Bonkovsky, H, Niederau, C, Rojkjaer, L, Weitzman, R, Williamson, P, Schoenborn-Kellenberger, O, Phatak, P

    Published in Journal of hepatology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    156P A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in advanced Epstein-Barr virus positive (EBV+) solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC)

    156P A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in advanced Epstein-Barr virus positive (EBV+) solid tumors and with pembrolizumab (PEM) in recurrent/me... by Colevas, A.D., Siu, L.L., Lim, D.W-T., Gao, B., Khan, S.A., Eng, L., Voon, P.J., Ahn, M-J., Elguindy, A., Katkov, A., Rojkjaer, L., Katz, Y., Ma, B.B.Y.

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Abstract P4-12-30: A bivalent Her2 targeting DARPin with high efficacy against Her2-low and Her2-positive tumors

    Abstract P4-12-30: A bivalent Her2 targeting DARPin with high efficacy against Her2-low and Her2-positive tumors by Dolado, I, Fiedler, U, Strobel, H, Metz, C, Stumpp, MT, Rojkjaer, L

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177 LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS

    LYMRIT 37‐01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177 LU‐LILOTOMAB SATETRAXETAN, A NOVEL CD37‐TARGETED ANTIBODY‐ RADIONUCLIDE‐CONJUGATE IN RELAPSED NHL PATIENTS by Kolstad, A., Madsbu, U., Beasley, M., Bayne, M., Illidge, T., O'Rourke, N., Lagerlöf, I., Hájek, R., Jurczak, W., Willenbacher, E., Blakkisrud, J., Muftuler Løndalen, A., Rojkjaer, L., Baylor Curtis, L., Bloma, M., Turner, S., Bolstad, N., Spetalen, S., Erlanson, M., Nygaard, S., Holte, H.

    Published in Hematological oncology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10

    Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-... by Ford, John M, Rojkjaer, Lisa

    Published in Haematologica (Roma)
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH)

    Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH) by Pietrangelo, A., Brissot, P., Bonkovsky, H., Niederau, C., Rojkjaer, L., Weitzman, R., Bodner, J., Bailey, S., Phatak, Pradyumna D.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity—a rebuttal

    Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity—a rebuttal by MAKRIS, M., VAN VEEN, J. J.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  10. 10
    Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs

    Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs by Wiinberg, B, Jensen, A.L, Rojkjaer, R, Johansson, P, Kjelgaard-Hansen, M, Kristensen, A.T

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: